Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- 6 September 2011
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (10), 947-954
- https://doi.org/10.1111/j.1463-1326.2011.01467.x
Abstract
Assess safety/tolerability and efficacy of the DPP-4 inhibitor vildagliptin in 515 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Double-blind, randomized, parallel-group, placebo-controlled, 24-week clinical trial assessing safety and efficacy of vildagliptin (50 mg qd) added to current antidiabetic therapy, in patients with T2DM and moderate or severe RI (GFR ≥ 30 to <50 or <30 ml/min/1.73 m(2) ). The study population comprised of 165 and 129 patients with moderate RI and 124 and 97 patients with severe RI randomized to vildagliptin and placebo, respectively, with most patients receiving background insulin therapy (68 and 81% for moderate and severe RI, respectively). After 24 weeks, the between-treatment difference in the adjusted mean change in A1C was -0.5 ± 0.1% (p < 0.0001) in moderate RI (baseline A1C = 7.9%) and -0.6 ± 0.1% (p < 0.0001) in severe RI (baseline A1C = 7.7%). In patients with moderate RI, similar proportions of those receiving vildagliptin or placebo experienced any AE (68 vs. 73%), any SAE (9 vs. 9%), any AE leading to discontinuation (3 vs. 5%) or death (1 vs. 1%). This was also true for patients with severe RI: AEs (73 vs. 74%), SAEs (19 vs. 21%), AEs leading to discontinuation (9 vs. 6%) and death (2 vs. 4%). In this 24-week study of 515 patients with T2DM and moderate or severe RI, vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo. Further, relative to placebo, vildagliptin elicited a statistically and clinically significant decrease in A1C in patients with moderate or severe RI.This publication has 20 references indexed in Scilit:
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes, Obesity and Metabolism, 2011
- Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studiesVascular Health and Risk Management, 2011
- Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsDiabetes, Obesity and Metabolism, 2010
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trialsDiabetes, Obesity and Metabolism, 2010
- Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes, Obesity and Metabolism, 2010
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysisBMC Endocrine Disorders, 2008
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*Diabetes, Obesity and Metabolism, 2008
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes, Obesity and Metabolism, 2008
- Management of Type 2 Diabetes in Treatment-Naive Elderly PatientsDiabetes Care, 2007
- Management of Glycemia in Patients With Diabetes Mellitus and CKDAmerican Journal of Kidney Diseases, 2007